Puriblood Medical Co., Ltd. (TPEX:6847)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
49.90
+0.05 (0.10%)
At close: Apr 24, 2026
Market Cap710.08M -51.1%
Revenue (ttm)117.35M -7.3%
Net Income-7.47M
EPS-0.53
Shares Out14.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume25,012
Average Volume33,458
Open49.85
Previous Close49.85
Day's Range49.75 - 52.30
52-Week Range47.75 - 90.70
Beta0.06
RSI31.94
Earnings DateApr 30, 2026

About Puriblood Medical

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan. [Read more]

Sector Healthcare
Founded 2015
Employees 44
Stock Exchange Taipei Exchange
Ticker Symbol 6847
Full Company Profile

Financial Performance

In 2024, Puriblood Medical's revenue was 110.67 million, a decrease of -11.65% compared to the previous year's 125.27 million. Losses were -5.37 million, -89.60% less than in 2023.

Financial Statements